Han-Chi Tseng

Han-Chi Tseng

Auto-generated profile, based on publicly available information

Han-Chi Tseng

Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine , Kaohsiung

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2020 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
YCYung-Wei Chang
Yung-Wei Chang
CLChih-Hung Lee
Chih-Hung Lee
HTHan-Chi Tseng
Han-Chi Tseng
Background/Purpose Leukemia cutis (LC), by definition, is the infiltration of neoplastic leukocytes in the skin. The overall incidence of LC is rare. We aimed to investigate the association between clinical characteristics, classifications and prognosis among different types of LC in Taiwan. Methods: We performed a retrospective analysis of forty-two patients with histopathology proven LC based on skin biopsies in a medical center in Southern Taiwan from 1997 to 2018. The study involved medical records of the patients, clinical manifestations, and outcomes according to different types of leukemia. Results: This series consisted of 27 males and 15 females, and the mean age was 55.7 years old. The most common cutaneous features were papules (38%) and nodules (29%), followed by plaques (16%) and ulcers (10%). The most commonly affected sites were the trunk (33%) and extremities (31.5%), although generalized distribution (14%) was not rare. The prognosis of LC was very poor, 76.2% of patients (32/42) died during the follow-up, and the median survival time was 7.2 months (95% CI, 4.53–9.87 months). No statistical significance was found (P = 0.068 for survival curves) among different types of LC. Conclusion: This study was the first large-scale research in regarding to LC of Han Chinese. The commonest clinical presentations were papules and nodules, and the predilection sites were trunk and extremities. Besides, there was the high frequency of LC from AML and MDS in Taiwan. Clinicians should pay more attention to the leukemia patients with extramedullary manifestations due to poor survival outcomes.

1 May 2021 in JAAD Case Reports
Verified
Journal Article
Open access
CSChia-Jui Su
Chia-Jui Su
HTHan-Chi Tseng
Han-Chi Tseng

1 July 2013 in Pancreatology
Verified
Journal Article
Closed access
HTHan-Chi Tseng
Han-Chi Tseng
CLChien-Ting Liu
Chien-Ting Liu
JHJi-Chen Ho
Ji-Chen Ho
SLShang-Hong Lin
Shang-Hong Lin

11 December 2020 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
YYYi‐Hsiang Yu
Yi‐Hsiang Yu
PSPei‐Lun Sun
Pei‐Lun Sun
CLChih-Hung Lee
Chih-Hung Lee
CSChia‐Jui Su
Chia‐Jui Su
HTHan‐Chi Tseng
Han‐Chi Tseng

21 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CYChin-Yi Yang
Chin-Yi Yang
PLPo-Ju Lai
Po-Ju Lai
CCChun-Bing Chen
Chun-Bing Chen
TCTom C. Chan
Tom C. Chan
RHRosaline Chung-Yee Hui
Rosaline Chung-Yee Hui
WCWenHung Chung
WenHung Chung
To determine phenotype-related dupilumab response in adult patients with atopic dermatitis (AD), this multicenter, retrospective study included 111 adults with moderate-to-severe AD in Taiwan, with median age of 31.5 years (18–87) and 71 (64.0%) males. Patients received dupilumab 300 mg per two to three weeks up to 12 months. We found a significant improvement after 4 and 16 weeks of treatment in all patients for all the assessed scores, including eczema area and severity index (EASI) improvement ≥50% (EASI-50) and 75% (EASI-75), EASI reaching minimal clinically important difference (MCID), and Investigator’s Global Assessment (IGA) improvement ≥2. Importantly, prior to asthma, early AD onset and 3-week drug intervals were significantly associated with a high proportion of EASI-75 at month 12, while prurigo and lichenoid phenotypes were associated with a lower proportion of EASI-75 at month 12. However, the majority of adverse events were mild in severity. In conclusion, our study results identify phenotype-related dupilumab response at month 12 in adults with moderate-to-severe AD, and we suggest that treatment should not be discontinued until reaching a satisfactory clinical response.